Paul L Reiter1, Gabriela Bustamante2, Annie-Laurie McRee3. 1. College of Public Health, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Electronic address: reiter.36@osu.edu. 2. Program in Health Disparities Research, University of Minnesota, Minneapolis, MN, USA; School of Medicine, Universidad San Francisco de Quito, Quito, Ecuador. 3. Division of General Pediatrics and Adolescent Health, University of Minnesota Medical School, Minneapolis, MN, USA.
Abstract
BACKGROUND: Sexual minority women (lesbian, bisexual, and other women who have sex with women) are at risk for human papillomavirus (HPV) infection and HPV-related disease, demonstrating the importance of HPV vaccination for these women. METHODS: We conducted an online survey of sexual minority women ages 18-45 from the United States (n = 505) in October 2019, about two months after HPV vaccine recommendations were expanded to include ages 27-45. Multivariable Poisson regression identified correlates of HPV vaccine initiation (i.e., receipt of at least one HPV vaccine dose). RESULTS: Overall, 65% of participants ages 18-26 and 33% of participants ages 27-45 had initiated the HPV vaccine series. Among participants ages 18-26, initiation was more common among those who had received a healthcare provider recommendation (RR = 2.19, 95% CI: 1.64-2.93) or had disclosed their sexual orientation to their primary healthcare provider (RR = 1.33, 95% CI: 1.07-1.65). Among initiators ages 27-45, a large majority (89%) reported receiving their first dose before turning age 27. Initiation was more common among participants ages 27-45 who had received a healthcare provider recommendation (RR = 3.23, 95% CI: 2.31-4.53) or who reported greater perceived social support for HPV vaccination (RR = 1.22, 95% CI: 1.05-1.40). Several reasons for not yet getting HPV vaccine differed by age group (ages 18-26 vs. ages 27-45; all p < 0.05). CONCLUSIONS: Many sexual minority women, particularly those ages 27-45, remain unvaccinated against HPV. Findings provide early insight into HPV vaccine coverage among adult women and highlight key leverage points for increasing vaccination among this population.
BACKGROUND: Sexual minority women (lesbian, bisexual, and other women who have sex with women) are at risk for human papillomavirus (HPV) infection and HPV-related disease, demonstrating the importance of HPV vaccination for these women. METHODS: We conducted an online survey of sexual minority women ages 18-45 from the United States (n = 505) in October 2019, about two months after HPV vaccine recommendations were expanded to include ages 27-45. Multivariable Poisson regression identified correlates of HPV vaccine initiation (i.e., receipt of at least one HPV vaccine dose). RESULTS: Overall, 65% of participants ages 18-26 and 33% of participants ages 27-45 had initiated the HPV vaccine series. Among participants ages 18-26, initiation was more common among those who had received a healthcare provider recommendation (RR = 2.19, 95% CI: 1.64-2.93) or had disclosed their sexual orientation to their primary healthcare provider (RR = 1.33, 95% CI: 1.07-1.65). Among initiators ages 27-45, a large majority (89%) reported receiving their first dose before turning age 27. Initiation was more common among participants ages 27-45 who had received a healthcare provider recommendation (RR = 3.23, 95% CI: 2.31-4.53) or who reported greater perceived social support for HPV vaccination (RR = 1.22, 95% CI: 1.05-1.40). Several reasons for not yet getting HPV vaccine differed by age group (ages 18-26 vs. ages 27-45; all p < 0.05). CONCLUSIONS: Many sexual minority women, particularly those ages 27-45, remain unvaccinated against HPV. Findings provide early insight into HPV vaccine coverage among adult women and highlight key leverage points for increasing vaccination among this population.
Authors: Madina Agénor; Gabriel R Murchison; Jarvis T Chen; Deborah J Bowen; Meredith B Rosenthal; Sebastien Haneuse; Sydney Bryn Austin Journal: Health Serv Res Date: 2019-11-10 Impact factor: 3.402
Authors: Kayoll V Galbraith; Julia Lechuga; Coretta M Jenerette; Ltc Angelo D Moore; Mary H Palmer; Jill B Hamilton Journal: Soc Sci Med Date: 2016-04-30 Impact factor: 4.634
Authors: Brittany M Charlton; Sari L Reisner; Madina Agénor; Allegra R Gordon; Vishnudas Sarda; S Bryn Austin Journal: LGBT Health Date: 2017-05-03 Impact factor: 4.151
Authors: Annie-Laurie McRee; Abigail Shoben; Jose A Bauermeister; Mira L Katz; Electra D Paskett; Paul L Reiter Journal: Vaccine Date: 2018-01-10 Impact factor: 3.641
Authors: J M Marrazzo; L A Koutsky; K L Stine; J M Kuypers; T A Grubert; D A Galloway; N B Kiviat; H H Handsfield Journal: J Infect Dis Date: 1998-12 Impact factor: 5.226
Authors: Elissa Meites; Peter G Szilagyi; Harrell W Chesson; Elizabeth R Unger; José R Romero; Lauri E Markowitz Journal: MMWR Morb Mortal Wkly Rep Date: 2019-08-16 Impact factor: 17.586